Are specialty pharma CEOs worth their salt? – FiercePharma
0
Specialty drugmakers often find their treatments scrutinized, with critics wondering if they’re worth their sometimes high price tags. But what about their CEOs?
Sanford Bernstein analyst Ronny Gal set out on a quest for clues to understanding compensation decisions for the head honchos at 7 specialty drugmakers–Actavis ($ACT), Allergan ($AGN), Hospira ($HSP), Momenta ($MNTA), Mylan ($MYL) and Teva ($TEVA)–and for a basis on which to compare them, The Wall Street Journal’s Pharmalot reports. To do so, he took a look at those companies’ proxy statements filed between 2010 and 2013.
His findings? For one, compensation for the top 5 execs at each company averaged about $20 million a year with a compounded annual growth rate of 3%–and 43% of total exec team compensation went to the CEO…
Read more FiercePharma